Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury

David E. Moody, Dana N. Loury, Brucc D. Hammock, Boris H. Ruebner, John M. Cullen, James H. Hillman, David W. Hillman, M. Sambasiva Rao, W. Thomas London, Hei Won L Hann, Irving Millman, Martin J. Griffin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Reports of an increase in a serum epoxide hydrolase (sEH), immunochemically related to microsomal EH in humans and rats with hepatocellular carcinoma (HCC), suggested its use as a serum marker for this disease. We have now measured sEH levels (as either immunochemically determined content or enzyme activity) in a number of human and experimental models of liver disease. sEH was elevated above the normal range in at least 50% of individuals with HCC, including: 3 of 6 northern Californians; 4 of 7 Koreans with hepatitis B-associated HCC; hepatitis B-associated HCC in woodchucks; and male rats receiving chronic treatment with aflatoxin B, or ciprofibrate. sEH was rarely elevated in other forms of chronic liver disease. Only 2 of 9 Koreans with hepatitis B-associated cirrhosis, 1 of 8 carriers, but none with chronic active hepatitis or infection with no apparent liver disease had elevated sEH. In addition, no elevations were found in woodchucks with noncancerous viral hepatitis. In aflatoxin B1- and M1-treatcd rats sEH was not elevated in those with only hyperplastic foci or hepatocellular adenomas, and in two rat initiation-promotion protocols sEH was elevated only in those rats which received the entire set of treatments. sEH was also increased during acute hepalotoxicity in rats treated with CCl4 or 1,2-dibromo-3-chloropropane. The mechanism of increase in sEH during hepatocarcinogenesis appears to be different from that of other markers of HCC, for in the Korean patients, there was no correlation between sEH concentrations and those of α-fetoprotein or ferritin, nor was there a correlation with α-fetoprotein concentrations in the aflatoxin-treated rats. Furthermore, the increase in sEH does not correlate with induction of microsomal EH in the liver of experimental animals. Studies to date indicate that sEH is selective for HCC and severe hepatonecrotic injury, and may be of some use in the diagnosis of HCC, particularly as a complement to other serum markers.

Original languageEnglish (US)
Pages (from-to)395-403
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume1
Issue number5
StatePublished - 1992

Fingerprint

Epoxide Hydrolases
Antigens
Liver
Wounds and Injuries
Serum
Hepatocellular Carcinoma
Hepatitis B
Marmota
Fetal Proteins
Liver Diseases
Aflatoxin B1
Biomarkers
Aflatoxin M1
Liver Cell Adenoma
Aflatoxins
Chronic Hepatitis
Ferritins
Hepatitis
Reference Values
Fibrosis

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Moody, D. E., Loury, D. N., Hammock, B. D., Ruebner, B. H., Cullen, J. M., Hillman, J. H., ... Griffin, M. J. (1992). Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury. Cancer Epidemiology Biomarkers and Prevention, 1(5), 395-403.

Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury. / Moody, David E.; Loury, Dana N.; Hammock, Brucc D.; Ruebner, Boris H.; Cullen, John M.; Hillman, James H.; Hillman, David W.; Rao, M. Sambasiva; London, W. Thomas; Hann, Hei Won L; Millman, Irving; Griffin, Martin J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 1, No. 5, 1992, p. 395-403.

Research output: Contribution to journalArticle

Moody, DE, Loury, DN, Hammock, BD, Ruebner, BH, Cullen, JM, Hillman, JH, Hillman, DW, Rao, MS, London, WT, Hann, HWL, Millman, I & Griffin, MJ 1992, 'Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury', Cancer Epidemiology Biomarkers and Prevention, vol. 1, no. 5, pp. 395-403.
Moody DE, Loury DN, Hammock BD, Ruebner BH, Cullen JM, Hillman JH et al. Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury. Cancer Epidemiology Biomarkers and Prevention. 1992;1(5):395-403.
Moody, David E. ; Loury, Dana N. ; Hammock, Brucc D. ; Ruebner, Boris H. ; Cullen, John M. ; Hillman, James H. ; Hillman, David W. ; Rao, M. Sambasiva ; London, W. Thomas ; Hann, Hei Won L ; Millman, Irving ; Griffin, Martin J. / Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury. In: Cancer Epidemiology Biomarkers and Prevention. 1992 ; Vol. 1, No. 5. pp. 395-403.
@article{1325475479714feb9f40efe8ca3d76bf,
title = "Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury",
abstract = "Reports of an increase in a serum epoxide hydrolase (sEH), immunochemically related to microsomal EH in humans and rats with hepatocellular carcinoma (HCC), suggested its use as a serum marker for this disease. We have now measured sEH levels (as either immunochemically determined content or enzyme activity) in a number of human and experimental models of liver disease. sEH was elevated above the normal range in at least 50{\%} of individuals with HCC, including: 3 of 6 northern Californians; 4 of 7 Koreans with hepatitis B-associated HCC; hepatitis B-associated HCC in woodchucks; and male rats receiving chronic treatment with aflatoxin B, or ciprofibrate. sEH was rarely elevated in other forms of chronic liver disease. Only 2 of 9 Koreans with hepatitis B-associated cirrhosis, 1 of 8 carriers, but none with chronic active hepatitis or infection with no apparent liver disease had elevated sEH. In addition, no elevations were found in woodchucks with noncancerous viral hepatitis. In aflatoxin B1- and M1-treatcd rats sEH was not elevated in those with only hyperplastic foci or hepatocellular adenomas, and in two rat initiation-promotion protocols sEH was elevated only in those rats which received the entire set of treatments. sEH was also increased during acute hepalotoxicity in rats treated with CCl4 or 1,2-dibromo-3-chloropropane. The mechanism of increase in sEH during hepatocarcinogenesis appears to be different from that of other markers of HCC, for in the Korean patients, there was no correlation between sEH concentrations and those of α-fetoprotein or ferritin, nor was there a correlation with α-fetoprotein concentrations in the aflatoxin-treated rats. Furthermore, the increase in sEH does not correlate with induction of microsomal EH in the liver of experimental animals. Studies to date indicate that sEH is selective for HCC and severe hepatonecrotic injury, and may be of some use in the diagnosis of HCC, particularly as a complement to other serum markers.",
author = "Moody, {David E.} and Loury, {Dana N.} and Hammock, {Brucc D.} and Ruebner, {Boris H.} and Cullen, {John M.} and Hillman, {James H.} and Hillman, {David W.} and Rao, {M. Sambasiva} and London, {W. Thomas} and Hann, {Hei Won L} and Irving Millman and Griffin, {Martin J.}",
year = "1992",
language = "English (US)",
volume = "1",
pages = "395--403",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury

AU - Moody, David E.

AU - Loury, Dana N.

AU - Hammock, Brucc D.

AU - Ruebner, Boris H.

AU - Cullen, John M.

AU - Hillman, James H.

AU - Hillman, David W.

AU - Rao, M. Sambasiva

AU - London, W. Thomas

AU - Hann, Hei Won L

AU - Millman, Irving

AU - Griffin, Martin J.

PY - 1992

Y1 - 1992

N2 - Reports of an increase in a serum epoxide hydrolase (sEH), immunochemically related to microsomal EH in humans and rats with hepatocellular carcinoma (HCC), suggested its use as a serum marker for this disease. We have now measured sEH levels (as either immunochemically determined content or enzyme activity) in a number of human and experimental models of liver disease. sEH was elevated above the normal range in at least 50% of individuals with HCC, including: 3 of 6 northern Californians; 4 of 7 Koreans with hepatitis B-associated HCC; hepatitis B-associated HCC in woodchucks; and male rats receiving chronic treatment with aflatoxin B, or ciprofibrate. sEH was rarely elevated in other forms of chronic liver disease. Only 2 of 9 Koreans with hepatitis B-associated cirrhosis, 1 of 8 carriers, but none with chronic active hepatitis or infection with no apparent liver disease had elevated sEH. In addition, no elevations were found in woodchucks with noncancerous viral hepatitis. In aflatoxin B1- and M1-treatcd rats sEH was not elevated in those with only hyperplastic foci or hepatocellular adenomas, and in two rat initiation-promotion protocols sEH was elevated only in those rats which received the entire set of treatments. sEH was also increased during acute hepalotoxicity in rats treated with CCl4 or 1,2-dibromo-3-chloropropane. The mechanism of increase in sEH during hepatocarcinogenesis appears to be different from that of other markers of HCC, for in the Korean patients, there was no correlation between sEH concentrations and those of α-fetoprotein or ferritin, nor was there a correlation with α-fetoprotein concentrations in the aflatoxin-treated rats. Furthermore, the increase in sEH does not correlate with induction of microsomal EH in the liver of experimental animals. Studies to date indicate that sEH is selective for HCC and severe hepatonecrotic injury, and may be of some use in the diagnosis of HCC, particularly as a complement to other serum markers.

AB - Reports of an increase in a serum epoxide hydrolase (sEH), immunochemically related to microsomal EH in humans and rats with hepatocellular carcinoma (HCC), suggested its use as a serum marker for this disease. We have now measured sEH levels (as either immunochemically determined content or enzyme activity) in a number of human and experimental models of liver disease. sEH was elevated above the normal range in at least 50% of individuals with HCC, including: 3 of 6 northern Californians; 4 of 7 Koreans with hepatitis B-associated HCC; hepatitis B-associated HCC in woodchucks; and male rats receiving chronic treatment with aflatoxin B, or ciprofibrate. sEH was rarely elevated in other forms of chronic liver disease. Only 2 of 9 Koreans with hepatitis B-associated cirrhosis, 1 of 8 carriers, but none with chronic active hepatitis or infection with no apparent liver disease had elevated sEH. In addition, no elevations were found in woodchucks with noncancerous viral hepatitis. In aflatoxin B1- and M1-treatcd rats sEH was not elevated in those with only hyperplastic foci or hepatocellular adenomas, and in two rat initiation-promotion protocols sEH was elevated only in those rats which received the entire set of treatments. sEH was also increased during acute hepalotoxicity in rats treated with CCl4 or 1,2-dibromo-3-chloropropane. The mechanism of increase in sEH during hepatocarcinogenesis appears to be different from that of other markers of HCC, for in the Korean patients, there was no correlation between sEH concentrations and those of α-fetoprotein or ferritin, nor was there a correlation with α-fetoprotein concentrations in the aflatoxin-treated rats. Furthermore, the increase in sEH does not correlate with induction of microsomal EH in the liver of experimental animals. Studies to date indicate that sEH is selective for HCC and severe hepatonecrotic injury, and may be of some use in the diagnosis of HCC, particularly as a complement to other serum markers.

UR - http://www.scopus.com/inward/record.url?scp=0026893706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026893706&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 395

EP - 403

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -